Drug Safety

, Volume 27, Issue 1, pp 25–61 | Cite as

Antimalarial Drug Toxicity

A Review
Review Article

Abstract

Malaria, caused mostly by Plasmodium falciparum and P. vivax, remains one of the most important infectious diseases in the world. Antimalarial drug toxicity is one side of the risk-benefit equation and is viewed differently depending upon whether the clinical indication for drug administration is malaria treatment or prophylaxis. Drug toxicity must be acceptable to patients and cause less harm than the disease itself. Research that leads to drug registration tends to omit two important groups who are particularly vulnerable to malaria — very young children and pregnant women. Prescribing in pregnancy is a particular problem for clinicians because the risk-benefit ratio is often very unclear.

The number of antimalarial drugs in use is very small. Despite its decreasing efficacy against P. falciparum, chloroquine continues to be used widely because of its low cost and good tolerability. It remains the drug of first choice for treating P. vivax malaria. Pruritus is a common adverse effect in African patients. As prophylaxis, chloroquine is usually combined with proguanil. This combination has good overall tolerability but mouth ulcers and gastrointestinal upset are more common than with other prophylactic regimens. Sulfadoxine/pyrimethamine is well tolerated as treatment and when used as intermittent preventive treatment in pregnant African women. Sulfadoxine/pyrimethamine is no longer used as prophylaxis because it may cause toxic epidermal necrolysis and Stevens Johnson syndrome. Mefloquine remains a valuable drug for prophylaxis and treatment. Tolerability is acceptable to most patients and travellers despite the impression given by the lay press. Dose-related serious neuropsychiatric toxicity can occur; mefloquine is contraindicated in individuals with a history of epilepsy or psychiatric disease. Quinine is the mainstay for treating severe malaria in many countries. Cardiovascular or CNS toxicity is rare, but hypoglycaemia may be problematic and blood glucose levels should be monitored. Halofantrine is unsuitable for widespread use because of its potential for cardiotoxicity.

There is renewed interest in two old drugs, primaquine and amodiaquine. Primaquine is being developed as prophylaxis, and amodiaquine, which was withdrawn from prophylactic use because of neutropenia and hepatitis, is a potentially good partner drug for artesunate against falciparum malaria. Atovaquone/proguanil is a new antimalarial combination with good efficacy and tolerability as prophylaxis and treatment. The most important class of drugs that could have a major impact on malaria control is the artemisinin derivatives. They have remarkable efficacy and an excellent safety record. They have no identifiable dose-related adverse effects in humans and only very rarely produce allergic reactions. Combining an artemisinin derivative with another efficacious antimalarial drug is increasingly being viewed as the optimal therapeutic strategy for malaria.

References

  1. 1.
    WHO. World malaria situation in 1994. Wkly Epidemiol Rec 1997; 72: 269-76Google Scholar
  2. 2.
    Snow RN, Craig M, Deichmann U, et al. Estimating mortality, morbidity and disability due to malaria among Africa’s nonpregnant population. Bull World Health Organ 1999; 77: 624–40PubMedGoogle Scholar
  3. 3.
    Bossuyt PMM. Better standards for better reporting of RCTs: a revised CONSORT statement should further improve standards of reporting. BMJ 2001; 322: 1317–8PubMedCrossRefGoogle Scholar
  4. 4.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9PubMedCrossRefGoogle Scholar
  5. 5.
    Nosten F, ter Kuile F, Maelankirri L, et al. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 1991; 85: 424–9PubMedCrossRefGoogle Scholar
  6. 6.
    Ahmed Y, Mwaba P, Chintu C, et al. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999; 3: 675–80PubMedGoogle Scholar
  7. 7.
    Krogstad DJ. Malaria as a re-emerging disease. Epidemiol Rev 1996; 18(1): 77–89PubMedCrossRefGoogle Scholar
  8. 8.
    Fox W. Self-administration of medicaments: a review of published work and a study of the problems. Bull Int Union Tuberc 1962; 32: 307–31PubMedGoogle Scholar
  9. 9.
    White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353: 1965–7PubMedCrossRefGoogle Scholar
  10. 10.
    Martindale Pharmacopoeia. Royal Pharmaceutical Society of Great Britain. 32nd edition. In: Parfitt K, editor. London; Pharmaceutical Press, 1999: 426–30Google Scholar
  11. 11.
    Mnyika KS, Kihamia CM. Chloroquine-induced pruritus: its impact on chloroquine utilization in malaria control in Dar es Salaam. J Trop Med Hyg 1991; 94: 27–31PubMedGoogle Scholar
  12. 12.
    Sowunmi A, Walker O, Salako LA. Pruritus and antimalarial drugs in Africans. Lancet 1989; II: 213CrossRefGoogle Scholar
  13. 13.
    Bussaratid V, Walsh DS, Wilairatana P, et al. Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand. Trop Doct 2000; 30: 211–4PubMedGoogle Scholar
  14. 14.
    Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221–5PubMedCrossRefGoogle Scholar
  15. 15.
    Olsen TG. Chloroquine and psoriasis. Ann Intern Med 1981; 94: 546–7PubMedGoogle Scholar
  16. 16.
    Wilairatana P, Looareesuwan S, Riganti M, et al. Pustular eruption in a malaria patient treated with chloroquine. Int J Dermatol 1997; 36: 634–5PubMedCrossRefGoogle Scholar
  17. 17.
    Millard TP, Smith HR, Lack MM, et al. Bullous pemphigoid developing during systemic therapy with chloroquine. Clin Exp Dermatol 1999; 24: 263–5PubMedCrossRefGoogle Scholar
  18. 18.
    Stemberger H, Leimer R, Wiedermann G. Tolerability of long-term prophylaxis with Fansidar: a randomized double blind study in Nigeria. Acta Trop 1984; 41: 391–9PubMedGoogle Scholar
  19. 19.
    Tanenbaum L, Tuffanelli DL. Antimalarial agents. Arch Dermatol 1980; 116: 587–91PubMedCrossRefGoogle Scholar
  20. 20.
    Fogh S, Schapira A, Bygbjerg IC, et al. Malaria prophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. BMJ 1988; 296: 820–2PubMedCrossRefGoogle Scholar
  21. 21.
    Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341: 1299–303PubMedCrossRefGoogle Scholar
  22. 22.
    Barrett PJ, Emmins PD, Clarke PD, et al. Comparison ofadverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone surveys of travellers. BMJ 1996; 313: 525–8PubMedCrossRefGoogle Scholar
  23. 23.
    Durrheim DN, Gammon S, Waner S, et al. Antimalarial prophylaxis: use and adverse events in visitors to the Kruger National Park. S Afr Med J 1999; 89: 170–5PubMedGoogle Scholar
  24. 24.
    Carme B, Peguet C, Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997; 2: 953–6PubMedCrossRefGoogle Scholar
  25. 25.
    Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers [letter]. Lancet 1990; 335: 164PubMedCrossRefGoogle Scholar
  26. 26.
    Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52: 269–75PubMedCrossRefGoogle Scholar
  27. 27.
    Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al. Incidence of myopathy in patients treated with antimalarials: a report of three cases and a review of the literature. Br J Rheumatol 1995; 34: 166–70PubMedCrossRefGoogle Scholar
  28. 28.
    Boffa MJ, Chalmers RJG. Toxic epidermal necrolysis due to chloroquine phosphate. Br J Dermatol 1994; 131: 444–5PubMedCrossRefGoogle Scholar
  29. 29.
    Bamber MG, Elder AT, Gray JA, et al. Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine. J Infect 1986; 13: 31–3PubMedCrossRefGoogle Scholar
  30. 30.
    Nagaratnam N, Chetiyawardana AD, Rajiyah S. Aplasia and leukaemia following chloroquine therapy. Postgrad Med J 1978; 54: 108–12PubMedCrossRefGoogle Scholar
  31. 31.
    Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997; 36: 599–601PubMedCrossRefGoogle Scholar
  32. 32.
    Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799–805PubMedCrossRefGoogle Scholar
  33. 33.
    WHO. Practical chemotherapy of malaria: report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1990; 805: 1–141Google Scholar
  34. 34.
    Fish DR, Espir MLE. Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. BMJ 1988; 297: 526–7PubMedCrossRefGoogle Scholar
  35. 35.
    Jaeger A, Sauder P, Kopferschmitt J, et al. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp 1987; 2: 242–73PubMedCrossRefGoogle Scholar
  36. 36.
    Riou B, Barriot P, Rimailho A, et al. Treatment of severe chloroquine poisoning. N Engl J Med 1988; 318: 1–6PubMedCrossRefGoogle Scholar
  37. 37.
    White NJ, Miller KD, Churchill FC, et al. Chloroquine treatment of severe malaria in children: pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319: 1493–500PubMedCrossRefGoogle Scholar
  38. 38.
    Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull WHO 1994; 72: 89–99PubMedGoogle Scholar
  39. 39.
    Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf 1996; 14 (3): 131–45Google Scholar
  40. 40.
    Wolfe M, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. BMJ 1985; 290: 1466–7PubMedCrossRefGoogle Scholar
  41. 41.
    Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55(1 Suppl.): 50–6PubMedGoogle Scholar
  42. 42.
    Klinger G, Morad M, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 385: 813–4CrossRefGoogle Scholar
  43. 43.
    Motta M, Tincani A, Faden D, et al. Antimalarial agents in pregnancy. Lancet 2002; 359: 524–5PubMedCrossRefGoogle Scholar
  44. 44.
    Ogunbona FA, Onyeji CO, Bolaji OO, et al. Excretion of chloroquine and desethylchloroquine in human milk. Br J Pharmacol 1987; 23: 473–6CrossRefGoogle Scholar
  45. 45.
    Edstein MD, Veenendaal JR, Newman K, et al. Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol 1986; 22: 733–5PubMedCrossRefGoogle Scholar
  46. 46.
    British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain (London). 2003 Mar; 45: 312–21Google Scholar
  47. 47.
    World Health Organisation. International travel and health. Geneva: WHO, 2002Google Scholar
  48. 48.
    Salako L, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci 1984; 13: 177–82PubMedGoogle Scholar
  49. 49.
    Bradley DJ, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2001. Commun Dis Public Health 2001; 4: 84–101PubMedGoogle Scholar
  50. 50.
    Cardiff Porphyria Service [online]. Available from URL: http://www.uwcm.ac.uk [Accessed 2003 Jan]
  51. 51.
    Sarkany RPE. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26: 225–32Google Scholar
  52. 52.
    Thornsvard CT, Guider BA, Kimball DB. An unusual reaction to chloroquine-primaquine. JAMA 1976; 235: 1719–20PubMedCrossRefGoogle Scholar
  53. 53.
    Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19: 1724–6PubMedGoogle Scholar
  54. 54.
    Damstra RJ, van Vloten A. Exacerbation of psoriasis caused by malaria prophylaxis with chloroquine and proguanil. Ned Tijdschr Geneeskd 1991; 135: 671–3PubMedGoogle Scholar
  55. 55.
    Luzar MJ. Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. J Rheumatol 1982; 9: 462–4PubMedGoogle Scholar
  56. 56.
    Looareesuwan S, Harinasuta T, Chongsuphajaisiddhi T. Drug resistant malaria, with special reference to Thailand. Southeast Asian J Trop Med Public Health 1992; 23: 621–34PubMedGoogle Scholar
  57. 57.
    Tierney LM, McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. New York (NY): McGraw Hill, 2000: 1504Google Scholar
  58. 58.
    Ekue JMK, Phiri DED, Sheth UK, et al. A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. Bull WHO 1987; 65: 369–73PubMedGoogle Scholar
  59. 59.
    Tjitra E, Suprianto S, Currie BJ, et al. Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg 2001; 65: 309–17PubMedGoogle Scholar
  60. 60.
    Tropical Disease Research [TDR]. (Data on file)Google Scholar
  61. 61.
    Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travellers using pyrimethamine-sulfadoxine (Fansidar®) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451–8Google Scholar
  62. 62.
    Steffen R, Somaini B. Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland [letter]. Lancet 1986; I: 610CrossRefGoogle Scholar
  63. 63.
    Olsen VV, Loft S, Christensen KD. Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine [letter]. Lancet 1982; II: 994CrossRefGoogle Scholar
  64. 64.
    US Department of Health and Human Services. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria. JAMA 1985;253: 483Google Scholar
  65. 65.
    Phillips-Howard PA, West L. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83: 82–5PubMedGoogle Scholar
  66. 66.
    Hellgren U, Rombo L, Berg B, et al. Adverse reactions to sulfadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis [letter]. BMJ 1988; 297: 1267PubMedCrossRefGoogle Scholar
  67. 67.
    Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 1985; II: 1072–3CrossRefGoogle Scholar
  68. 68.
    Bergoend H, Loffler A, Amar R, et al. Reactions cutanees survenues au cours de la prophylaxie de masse de la meningite cerebro-spinale par un sulfamide long-retard (propos de 997 cas). Ann Dermatol Venereol 1968; 95: 481–90Google Scholar
  69. 69.
    Taylor GM. Stevens-Johnson syndrome following the use of an ultra-long-acting sulphonamide. S Afr Med J 1968; 42: 501–3PubMedGoogle Scholar
  70. 70.
    Phillips-Howard PA, Behrens RH, Dunlop J. Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria. Lancet 1989; II: 803–4CrossRefGoogle Scholar
  71. 71.
    Langtry JAA, Harper JI, Staughton RCD, et al. Erythroderma resembling Sezary syndrome after treatment with Fansidar and chloroquine. BMJ 1986; 292: 1107–8PubMedCrossRefGoogle Scholar
  72. 72.
    Lazar HO, Murphy RL, Phair JP. Fansidar and hepatic granulomas [letter]. Ann Intern Med 1985; 102: 722PubMedGoogle Scholar
  73. 73.
    Wejstal R, Lindberg J, Malmvall B E, et al. Liver damage associated with Fansidar. Lancet 1986; I: 854–5CrossRefGoogle Scholar
  74. 74.
    Tonder M, Nordy A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974; 9: 93–6PubMedGoogle Scholar
  75. 75.
    Zitelli BJ, Alexander J, Taylor S, et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 1987; 106: 393–5PubMedGoogle Scholar
  76. 76.
    Selby CD, Ladusans EJ, Smith PG. Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar). BMJ 1985; 290: 113–4PubMedCrossRefGoogle Scholar
  77. 77.
    Svanbom M, Rombo L, Gustafsson L. Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar) [short report]. BMJ 1984; 288: 1876PubMedCrossRefGoogle Scholar
  78. 78.
    McCormack D, Morgan WKC. Fansidar hypersensitivity pneumonitis. Br J Dis Chest 1987; 81: 194–6PubMedCrossRefGoogle Scholar
  79. 79.
    Hitchings GH. Daraprim as an antagonist of folic and folinic acids. Trans R Soc Trop Med Hyg 1952; 46: 467PubMedCrossRefGoogle Scholar
  80. 80.
    Chute JP, Decker CF, Cotelingam J. Severe megaloblastic anemia complicating pyrimethamine therapy. Ann Intern Med 1995; 122: 884–5PubMedGoogle Scholar
  81. 81.
    Wickramasihghe SN, Litwinczuk RAC. Effects of low concentrations of pyrimethamine on human bone marrow cells in vitro: possible implications for malaria prophylaxis. J Trop Med Hyg 1981; 84: 233–8Google Scholar
  82. 82.
    Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ 1991; 69: 297–304PubMedGoogle Scholar
  83. 83.
    Lindberg A, Bergqvist Y, Rombo L. Accidental overdose of pyrimethamine and sulphadoxine for malaria prophylaxis without adverse effects. Eur J Clin Pharmacol 1986; 31: 253–4PubMedCrossRefGoogle Scholar
  84. 84.
    Burgmann H, Winkler S, Uhl F, et al. Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica. Wien Klin Wochenschr 1993; 105: 61–3PubMedGoogle Scholar
  85. 85.
    Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353: 632–6PubMedCrossRefGoogle Scholar
  86. 86.
    Verhoeff FH, Brabin BJ, Chimsuku L, et al. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998; 92: 141–50PubMedCrossRefGoogle Scholar
  87. 87.
    Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51: 515–22PubMedGoogle Scholar
  88. 88.
    Verhoeff FH, Brabin BJ, Hart CA, et al. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999; 4: 5–12PubMedCrossRefGoogle Scholar
  89. 89.
    Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 59: 813–22PubMedGoogle Scholar
  90. 90.
    Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990; 18(1): 20–36PubMedCrossRefGoogle Scholar
  91. 91.
    Izumi H, Kokue E, Hayama T. The critical period of pyrimethamine teratogenesis in the rat. Nippon Juigaku Zasshi 1984; 46: 217–8PubMedCrossRefGoogle Scholar
  92. 92.
    Harpey JP, Darbois Y, Lefebrve G. Teratogenicity of pyrimethamine [letter]. Lancet 1983; 399: 2Google Scholar
  93. 93.
    Pyrimethamine combinations in pregnancy. Lancet 1983 Oct; 29: 1005-7Google Scholar
  94. 94.
    Phillips-Howard PA, Steffen R, Kerr L, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998; 5: 121–6PubMedCrossRefGoogle Scholar
  95. 95.
    Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989; 115: 765–9PubMedCrossRefGoogle Scholar
  96. 96.
    International Standard Prescribing Information. Roche, May 1997Google Scholar
  97. 97.
    Bang AT, Bang RA, Baitule SB, et al. Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India. Lancet 1999; 354: 1955–61PubMedCrossRefGoogle Scholar
  98. 98.
    Nosten F, van Vugt M, Price R, et al. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356: 297–302PubMedCrossRefGoogle Scholar
  99. 99.
    Cerutti C, Durlacher RR, de Alencar FE, et al. In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. J Infect Dis 1999; 180: 2077–80PubMedCrossRefGoogle Scholar
  100. 100.
    Mockenhaupt FP. Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995; 11: 248–53PubMedCrossRefGoogle Scholar
  101. 101.
    Lobel HO, Varma JK, Miani M, et al. Monitoring for mefloquine- resistant Plasmodium falciparum in Africa: implications for travellers’ health. Am J Trop Med Hyg 1998; 59: 129–32PubMedGoogle Scholar
  102. 102.
    Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 963–72PubMedGoogle Scholar
  103. 103.
    Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341: 848–51PubMedCrossRefGoogle Scholar
  104. 104.
    Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054–6PubMedCrossRefGoogle Scholar
  105. 105.
    Nosten F, Price RN. New antimalarials: a risk-benefit analysis. Drug Saf 1995; 12(4): 264–73PubMedCrossRefGoogle Scholar
  106. 106.
    Kofi Ekue JM, Ulrich AM, Rwabwogo-Atenyi J, et al. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ 1983; 61: 713–8PubMedGoogle Scholar
  107. 107.
    ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341: 1044–9PubMedCrossRefGoogle Scholar
  108. 108.
    Looareesuwan S, Wilairatana P, Chokejindachai W, et al. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60: 238–43PubMedGoogle Scholar
  109. 109.
    van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42: 135–9PubMedGoogle Scholar
  110. 110.
    ter Kuile FO, Nosten F, Luxemburger C, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 1995; 73: 631–42PubMedGoogle Scholar
  111. 111.
    ter Kuile FO, Luxemburger C, Nosten F, et al. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89: 660–4PubMedCrossRefGoogle Scholar
  112. 112.
    Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr 1996; 16: 281–6PubMedGoogle Scholar
  113. 113.
    Price R, Simpson JA, Teja-Isavatharm P, et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother 1999; 43: 341–6PubMedGoogle Scholar
  114. 114.
    Luxemburger C, van Vugt M, Slight T, et al. Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Trans R Soc Trop Med Hyg 1998; 92: 562–3PubMedCrossRefGoogle Scholar
  115. 115.
    Slutsker LM, Khoromana CO, Payne D, et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 1990; 68: 53–9PubMedGoogle Scholar
  116. 116.
    Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 45: 430–75PubMedCrossRefGoogle Scholar
  117. 117.
    Nosten F, van Vugt. Neuropsychiatric adverse effects of mefloquine: what do we know and what should we do? CNS Drugs 1999; 11 (1): 1–8Google Scholar
  118. 118.
    Phillips-Howard PA, ter Kuile F. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf 1995; 12(6): 370–83PubMedCrossRefGoogle Scholar
  119. 119.
    Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Travel Med 1999; 6: 122–33PubMedCrossRefGoogle Scholar
  120. 120.
    WHO. Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985–1990). WHO/MAL/91.1063Google Scholar
  121. 121.
    Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45: 86–91PubMedGoogle Scholar
  122. 122.
    Sowunmi A, Salako LA, Oduola AMJ, et al. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg 1993; 87: 462–3PubMedCrossRefGoogle Scholar
  123. 123.
    Luxemburger C, Nosten F, ter Kuile F, et al. Mefloquine for multidrug-resistant malaria [letter]. Lancet 1991; 338: 1268PubMedCrossRefGoogle Scholar
  124. 124.
    ter Kuile F. Mefloquine, halofantrine and artesunate in the treatment of uncomplicated falciparum malaria in a multidrug resistant area [PhD thesis]. University of Amsterdam, 1994Google Scholar
  125. 125.
    Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet 1996; 348: 917–21PubMedCrossRefGoogle Scholar
  126. 126.
    Riemsdijk van RM, van der Klauw MM, vanHJ, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52: 1–6PubMedCrossRefGoogle Scholar
  127. 127.
    Sanchez JL, DeFraites RF, Sharp TW, et al. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993; 341: 1021–2PubMedCrossRefGoogle Scholar
  128. 128.
    Jaspers CA, Hopperus Buma AP, van Thiel PP, et al. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55: 230–4PubMedGoogle Scholar
  129. 129.
    Hopperus Buma AP, van Thiel PP, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173: 1506–9PubMedCrossRefGoogle Scholar
  130. 130.
    Steffen R, Heusser R, Machler R, et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use adverse reactions, and efficacy. Bull World Health Organ 1990; 68: 313–22PubMedGoogle Scholar
  131. 131.
    Bunnag D, Malikul S, Chittamas S, et al. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial. Southeast Asian J Trop Med Public Health 1992; 23: 777–82PubMedGoogle Scholar
  132. 132.
    Salako LA, Adio RA, Walker O, et al. Mefloquine-sulphadoxine- pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study. Ann Trop Med Parasitol 1992; 86: 575–81PubMedGoogle Scholar
  133. 133.
    Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44: 257–65PubMedGoogle Scholar
  134. 134.
    Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167–79PubMedGoogle Scholar
  135. 135.
    Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997; 315: 1412–6PubMedCrossRefGoogle Scholar
  136. 136.
    Schlagenhauf P, Lobel H, Steffen R, et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 1997; 56: 235–40PubMedGoogle Scholar
  137. 137.
    Vuurman E, Muntjewerrff N, Uiterwijk M, et al. Effects of mefloquine, alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996; 50: 475–82PubMedCrossRefGoogle Scholar
  138. 138.
    Hessen-Soderman AC, Bergenius Johan, Palme IB, et al. Mefloquine prophylaxis and hearing, postural control and vestibular functions. J Travel Med 1995; 2: 66–9PubMedCrossRefGoogle Scholar
  139. 139.
    Smith HR, Croft AM, Black MM. Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports. Clin Exp Dermatol 1999; 24: 263–5PubMedCrossRefGoogle Scholar
  140. 140.
    Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine inpatients with chloroquine-resistant falciparum malaria in Thailand. 1983; 61: 299–305Google Scholar
  141. 141.
    Fonteyne W, Bauwens A, Jordaens L. Atrial flutter with 1:1 conductino after administration of the antimalarial drug mefloquine. Clin Cardiol 1996; 19: 967–8PubMedCrossRefGoogle Scholar
  142. 142.
    Richter J, Burbach G, Hellgren U, et al. Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Lancet 1997; 349: 101–2PubMedCrossRefGoogle Scholar
  143. 143.
    Danis M, Nozais JP, Paris L, et al. Blackwater fever after ingestion of mefloquine: three cases [letter]. Presse Med 1993; 22: 80PubMedGoogle Scholar
  144. 144.
    Van den Ende J, Coppens G, Verstraeten T, et al. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 1998; 3: 632–9PubMedCrossRefGoogle Scholar
  145. 145.
    Hennequin C, Eouree P, Halfon P. Agranulocytosis during treatment with mefloquine. Lancet 1991; 265: 398–9Google Scholar
  146. 146.
    Gotsman I, Azaz-Livshits T, Fridlender Z, et al. Mefloquine-induced acute hepatitis. Pharmacotherapy 2000; 20: 1517–9PubMedCrossRefGoogle Scholar
  147. 147.
    Nicolas X, Granier H, Laborde JP, et al. Danger of malaria self-treatment: acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine. Presse Med 2001; 30: 1349–50PubMedGoogle Scholar
  148. 148.
    Steketee RW, Wirima JJ, Slutsker L, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 1996; 55(1 Suppl.): 24–32PubMedGoogle Scholar
  149. 149.
    Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994 169: 595–603PubMedCrossRefGoogle Scholar
  150. 150.
    McGready R, Cho T, Hkirijaroen L, et al. Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasitol 1998; 92: 643–53PubMedCrossRefGoogle Scholar
  151. 151.
    Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999; 28: 808–15PubMedCrossRefGoogle Scholar
  152. 152.
    Vanhauwere B, Maradit H, Kerr L. Post-market surveillance of prophylactic mefloquine (Larium®) use in pregnancy. Am J Trop Med Hyg 1998; 58: 17–21PubMedGoogle Scholar
  153. 153.
    Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis 1997; 176: 831–3PubMedCrossRefGoogle Scholar
  154. 154.
    Edstein MD, Veenendaal JR, Hyslop R. Excretion of mefloquine in human breast milk. Chemotherapy 1988; 34: 165–9PubMedCrossRefGoogle Scholar
  155. 155.
    International Standard Prescribing Information. Roche, May 1999Google Scholar
  156. 156.
    White NJ, Looareesuwan S, Warrell DA, et al. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 1983; 31: 1–5Google Scholar
  157. 157.
    Roche RJ, Silamut K, Pukrittayakamee S, et al. Quinine induces reversible high-tone hearing loss. Br J Clin Pharmacol 1990; 29: 780–2PubMedCrossRefGoogle Scholar
  158. 158.
    Claessen FA, van Boxtel CJ, Perenboom RM, et al. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 1998; 3: 482–9PubMedCrossRefGoogle Scholar
  159. 159.
    Waddell K. Blindness from quinine as an antimalarial. Trans R Soc Trop Med Hyg 1996; 90: 331–2PubMedCrossRefGoogle Scholar
  160. 160.
    Rheeder P, Sieling WL. Acute, persistent quinine-induced blindness: a case report. S Afr Med J 1991; 79: 563–4PubMedGoogle Scholar
  161. 161.
    Yospaiboon Y, Lawtiantong T, Chotibutr S. Clinical observations of ocular quinine intoxication. Jpn J Ophthalmol 1984; 28: 409–15PubMedGoogle Scholar
  162. 162.
    White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycaemia and hyperinsulinaemia in falciparum malaria. N Engl J Med 1983; 309: 61–6PubMedCrossRefGoogle Scholar
  163. 163.
    Okitolonda W, Dellacotte C, Malengreau M, et al. High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. BMJ 1987; 295: 716–8PubMedCrossRefGoogle Scholar
  164. 164.
    Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. Lancet 1985; II: 4–8CrossRefGoogle Scholar
  165. 165.
    WHO. Severe falciparum malaria: World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94 Suppl. 1: S1–90Google Scholar
  166. 166.
    Taylor WRJ, Prosser DI. Acute rhabdomyolysis, acute renal failure and falciparum malaria [short report]. Trans R Soc Trop Med Hyg 1992; 86: 361PubMedCrossRefGoogle Scholar
  167. 167.
    Limburg PJ, Katz H, Grant CS, et al. Quinine-induced hypoglycaemia. Ann Intern Med 1993; 119: 218–9PubMedGoogle Scholar
  168. 168.
    White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol 1983; 5: 173–5PubMedCrossRefGoogle Scholar
  169. 169.
    Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76–83PubMedCrossRefGoogle Scholar
  170. 170.
    Na-Bangchang K, Tan-Ariya P, Thanavibul A, et al. Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. Int J Clin Pharmacol Res 1999; 19: 73–82PubMedGoogle Scholar
  171. 171.
    Supanaranond W, Suputtamongkol Y, Davis TM, et al. Lack of a significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans R Soc Trop Med Hyg 1997; 91: 694–6PubMedCrossRefGoogle Scholar
  172. 172.
    Bonington A, Davidson RN, Winstanley PA, et al. Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Trans R Soc Trop Med Hyg 1996; 90: 305–7PubMedCrossRefGoogle Scholar
  173. 173.
    The Artemether-Quinine Meta-Analysis Study Group. A metaanalysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 2001; 95: 637–50Google Scholar
  174. 174.
    Bottiger LE, Furhoff AK, Holmberg L. Drug-induced blood dyscrasias: a ten-year material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205: 457–61PubMedCrossRefGoogle Scholar
  175. 175.
    Danielson DA, Douglas III SW, Herzog P, et al. Drug-induced blood disorders. JAMA 1984; 252: 3257–60PubMedCrossRefGoogle Scholar
  176. 176.
    Freiman JP. Fatal quinine-induced thrombocytopenia. Ann Intern Med 1990; 112: 308–9PubMedGoogle Scholar
  177. 177.
    Murray JA, Abbott I, Anderson DA, et al. Bitter lemon purpura. BMJ 1979; 2: 1551–2PubMedCrossRefGoogle Scholar
  178. 178.
    Brasic JR. Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps. Mayo Clin Proc 2001; 76: 863–4PubMedCrossRefGoogle Scholar
  179. 179.
    Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ 1995; 310: 13–7PubMedCrossRefGoogle Scholar
  180. 180.
    Tran TH, Day NP, Ly VC, et al. Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin Infect Dis 1996; 23: 1274–81PubMedCrossRefGoogle Scholar
  181. 181.
    Delacollette C, Taelman H, Wery M. An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire. Ann Soc Belg Med Trop 1995; 75: 51–63PubMedGoogle Scholar
  182. 182.
    Gottschall JL, Neahring B, McFarland JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994; 47: 283–9PubMedCrossRefGoogle Scholar
  183. 183.
    Webb RF, Ramirez AM, Hocken AG, et al. Acute intravascular haemolysis due to quinine. N Z Med J 1980; 91: 14–6PubMedGoogle Scholar
  184. 184.
    Spearing RL, Hickton CM, Sizeland P, et al. Quinine-induced disseminated intravascular coagulation. Lancet 1990; 336: 1535–7PubMedCrossRefGoogle Scholar
  185. 185.
    Maguire RB, Stroncek DF, Campbell AC. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies. Ann Intern Med 1993; 119: 215–7PubMedGoogle Scholar
  186. 186.
    Barr E, Douglas JF, Hill CM. Recurrent acute hypersensitivity to quinine [short report]. BMJ 1990; 301: 323PubMedCrossRefGoogle Scholar
  187. 187.
    Ljunggren B, Sjovall P. Systemic quinine photosensitivity. Arch Dermatol 1986; 122: 909–11PubMedCrossRefGoogle Scholar
  188. 188.
    Guzzo C, Kaidbey K. Persistent light reactivity from systemic quinine. Photodermatol Photoimmunol Photomed 1990; 7: 166–8PubMedGoogle Scholar
  189. 189.
    Price EJ, Bevan JS, Rees A. Quinine-induced cutaneous vasculitis. Br J Clin Pract 1992; 46: 138–9PubMedGoogle Scholar
  190. 190.
    Meyrick Thomas RH, Munro DD. Lichen planus in a photosensitive distribution due to quinine. Clin Exp Dermatol 1986; 11: 97–101PubMedCrossRefGoogle Scholar
  191. 191.
    Dawson TA. Side effect of quinine for nocturnal cramps [letter] BMJ 1995; 310: 738PubMedCrossRefGoogle Scholar
  192. 192.
    Hou M, Horney E, Stockelberg D, et al. Multiple quinine-dependent antibodies in a patient with episodic thrombocytopenia, neutropenia, lymphocytopenia, and granulomatous hepatitis. Blood ai]1997; 90: 4806–11PubMedGoogle Scholar
  193. 193.
    Punukollu RC, Kumar S, Mullen KD. Quinine hepatotoxicity: an underrecognized or rare phenomenon? Arch Intern Med 1990; 150: 1112–3PubMedCrossRefGoogle Scholar
  194. 194.
    Schapira A, Solomon T, Julien M, et al. Comparison of intramuscular and intravenous quinine for the treatment of severe and complicated malaria in children. Trans R Soc Trop Med Hyg 1993; 87: 299–302PubMedCrossRefGoogle Scholar
  195. 195.
    Pasvol G, Newton CR, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991; 45: 702–13PubMedGoogle Scholar
  196. 196.
    Ross R. Intramuscular injections of quinine. J Trop Med Hyg 1914; 17: 286–8Google Scholar
  197. 197.
    Yen LM, Dao LM, Day NP, et al. Role of quinine in the high mortality of intramuscular injection tetanus. Lancet 1994; 344: 786–7PubMedCrossRefGoogle Scholar
  198. 198.
    Silamut K, Molunto P, Ho M, et al. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 1991; 32: 311–5PubMedCrossRefGoogle Scholar
  199. 199.
    Powell RD, McNamara J. Quinine: side-effects and plasma levels. Proceedings of the Helminthological Society of Washington 1966; 30: 331–8Google Scholar
  200. 200.
    Karbwang J, Tin T, Rimchala W, et al. Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand. Trans R Soc Trop Med Hyg 1995; 89: 668–71PubMedCrossRefGoogle Scholar
  201. 201.
    Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88: 324–7PubMedCrossRefGoogle Scholar
  202. 202.
    Murphy S, English M, Waruiru C, et al. An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans R Soc Trop Med Hyg 1996; 90: 298–301PubMedCrossRefGoogle Scholar
  203. 203.
    Bethell DB, Phuong PT, Phuong CX, et al. Electrocardiographic monitoring in severe falciparum malaria. Trans R Soc Trop Med Hyg 1996; 90: 266–9PubMedCrossRefGoogle Scholar
  204. 204.
    Winstanley PA, Mberu EK, Watkins WM, et al. Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: unbound quinine concentrations following a simple loading dose regimen. Trans R Soc Trop Med Hyg 1994; 88: 577–80PubMedCrossRefGoogle Scholar
  205. 205.
    White NJ. Optimal regimens of parenteral quinine [letter]. Trans R Soc Trop Med Hyg 1995; 89: 462–4PubMedCrossRefGoogle Scholar
  206. 206.
    van Hensbroek MB, Kwiatkowski D, van den Berg B, et al. Quinine pharmacokinetics in young children with severe malaria. Am J Trop Med Hyg 1996; 54: 237–42PubMedGoogle Scholar
  207. 207.
    Boland ME, Roper SM, Henry JA. Complications of quinine poisoning. Lancet 1985; I: 384–5CrossRefGoogle Scholar
  208. 208.
    Dyson EH, Proudfoot AT, Prescott LF, et al. Death and blindness due to overdose of quinine. BMJ 1985; 291: 31–3PubMedCrossRefGoogle Scholar
  209. 209.
    Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med 1985; 54: 125–31PubMedGoogle Scholar
  210. 210.
    Caminade S, Ricome JL, Auzepy P. Intoxication aigues par quinine, quinidine et chloroquine: a propos de 18 cas. Journal des Agreges 1978; II: 613–8Google Scholar
  211. 211.
    Brinton GS, Norton EW, Zahn JR, et al. Ocular quinine toxicity. Am J Ophthalmol 1980; 90: 403–10PubMedGoogle Scholar
  212. 212.
    Mackie MA, Davidson J, Clarke J. Quinine: acute self-poisoning and ocular toxicity. Scott Med J 1997; 42: 8–9PubMedGoogle Scholar
  213. 213.
    Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988; 72: 219–24PubMedCrossRefGoogle Scholar
  214. 214.
    Wolff RS, Wirtschafter D, Adkinson C. Ocular quinine toxicity treated with hyperbaric oxygen. Undersea Hyperb Med 1997; 24: 131–4PubMedGoogle Scholar
  215. 215.
    Dannenberg AL, Dorfman SF, Johnson J. Use of quinine for self-induced abortion. South Med J 1983; 76: 846–9PubMedCrossRefGoogle Scholar
  216. 216.
    Winckel CWF. Quinine and congenital injuries of ear and eye of the fetus. J Trop Med Hyg 1948; 51: 2–7PubMedGoogle Scholar
  217. 217.
    McGready R, Nosten F. The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy. Ann Trop Med Parasitol 1999; 93Suppl. 1: S19–23PubMedCrossRefGoogle Scholar
  218. 218.
    McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002; 96: 180–4PubMedCrossRefGoogle Scholar
  219. 219.
    Phillips RE, Looareesuwan S, White NJ, et al. Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br J Clin Pharmacol 1986; 21: 677–83PubMedCrossRefGoogle Scholar
  220. 220.
    Watt G, Na-Nakorn A, Bateman DN, et al. Amplification of quinine cardiac effects by the resistance-reversing agent prochlorperazine in falciparum malaria. Am J Trop Med Hyg 1993; 49: 645–9PubMedGoogle Scholar
  221. 221.
    Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995; 17: 1678–82CrossRefGoogle Scholar
  222. 222.
    Fryauff DJ, Baird JK, Basri H, et al. Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. Ann Trop Med Parasitol 1997; 91: 7–16PubMedCrossRefGoogle Scholar
  223. 223.
    Brasseur P, Bitsindou P, Moyou RS, et al. Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet 1993; 341: 901–2PubMedCrossRefGoogle Scholar
  224. 224.
    Bouchaud O, Basco LK, Gillotin C, et al. Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am J Trop Med Hyg 1994; 51: 204–13PubMedGoogle Scholar
  225. 225.
    Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104–19PubMedCrossRefGoogle Scholar
  226. 226.
    Vincent MP, Becquart JP, Receveur MC, et al. Halofantrine overdosage [letter]. Presse Med 1992; 21: 131PubMedGoogle Scholar
  227. 227.
    Gillespie SH, Msaki EP, Ramsay A, et al. A new micronized formulation of halofantrine hydrochloride in the treatment of acute Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1993; 87: 467–9PubMedCrossRefGoogle Scholar
  228. 228.
    Salako LA, Sowunmi A, Walker O. Evaluation of the clinical efficacy and safety of halofantrine in falciparum malaria in Ibadan, Nigeria. Trans R Soc Trop Med Hyg 1990; 84: 644–7PubMedCrossRefGoogle Scholar
  229. 229.
    Coulaud JP, Le Bras J, Matheron S, et al. Treatment of imported cases of falciparum malaria in France with halofantrine. Trans R Soc Trop Med Hyg 1986; 80: 615–7PubMedCrossRefGoogle Scholar
  230. 230.
    Mojon M, Wallon M, Gravey A, et al. Intravascular haemolysis following halofantrine intake [short report]. Trans R Soc Trop Med Hyg 1994; 88: 91PubMedCrossRefGoogle Scholar
  231. 231.
    Vachon F, Fajac I, Gachot B, et al. Halofantrine and acute intravascular haemolysis. Lancet 1992; 340: 909–10PubMedCrossRefGoogle Scholar
  232. 232.
    Hasiba K, Os AJ, Schwartz PJ. QT prolongation and ventricular arrhythmias. Ann N Y Acad Sci 1992; 666: 1a–245aCrossRefGoogle Scholar
  233. 233.
    Milton KA, Edwards G, Ward SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71–7PubMedCrossRefGoogle Scholar
  234. 234.
    Monlun E, Le Metayer P, Szwandt S, et al. ardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995; 89: 430–3PubMedCrossRefGoogle Scholar
  235. 235.
    Hombhanje FW, Kereu RK, Bulungol P, et al. Halofantrine in the treatment of uncomplicated falciparum malaria with a three-dose regimen in Papua New Guinea: a preliminary report. P N G Med J 1998; 41: 23–9PubMedGoogle Scholar
  236. 236.
    Touze JE, Bernard J, Keundjian A, et al. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996; 54: 225–8PubMedGoogle Scholar
  237. 237.
    Gundersen SG, Rostrup M, von der Lippe E, et al. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand J Infect Dis 1997; 29: 207–8PubMedCrossRefGoogle Scholar
  238. 238.
    Malvy D, Receveur MC, Ozon P, et al. Fatal cardiac incident after use of halofantrine. J Travel Med 2000; 7: 215–6PubMedCrossRefGoogle Scholar
  239. 239.
    Sowunmi A, Falade CO, Oduola AM, et al. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1998; 92: 446–8PubMedCrossRefGoogle Scholar
  240. 240.
    Schuster BG, Canfield CJ. Preclinical studies with halofantrine in halofantrine in the treatment of multidrug resistant malaria. Parasitol Today 1989; Suppl.: 65–79Google Scholar
  241. 241.
    Touze JE, Fourcade L, Peyron F, et al. Is halofantrine still advisable in malaria attacks? Ann Trop Med Parasitol 1997; 91: 867–73PubMedCrossRefGoogle Scholar
  242. 242.
    Matson PA, Luby SP, Redd SC, et al. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996; 54: 229–31PubMedGoogle Scholar
  243. 243.
    Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovoquone-proguanil (Malarone®) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95: 429–32PubMedCrossRefGoogle Scholar
  244. 244.
    Radloff RD, Philipps J, Hutchinson D, et al. Atovoquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria [short report]. Trans R Soc Trop Med Hyg 1996; 90: 682PubMedCrossRefGoogle Scholar
  245. 245.
    Looareesuwan S, Wilairatana P, Glanarongran R, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 1999; 93: 637–40PubMedCrossRefGoogle Scholar
  246. 246.
    Lell B, Luckner D, Ndjave M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351: 709–13PubMedCrossRefGoogle Scholar
  247. 247.
    Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27: 494–9PubMedCrossRefGoogle Scholar
  248. 248.
    Sukwa TY, Mulenga M, Chisdaka NS, et al. A randomised, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60: 521–5PubMedGoogle Scholar
  249. 249.
    Hogh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000; 356: 1888–94PubMedCrossRefGoogle Scholar
  250. 250.
    Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travellers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015–21PubMedCrossRefGoogle Scholar
  251. 251.
    Bustos DG, Canfield CJ, Canete-Miguel E, et al. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999; 179: 1587–90PubMedCrossRefGoogle Scholar
  252. 252.
    Rolan PE, Mercer AJ, Weatherley BC, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994 Jan; 37: 13–20PubMedCrossRefGoogle Scholar
  253. 253.
    Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60: 526–32PubMedGoogle Scholar
  254. 254.
    Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347: 1511–4PubMedCrossRefGoogle Scholar
  255. 255.
    Bouchaud O, Monlun E, Muanza K, et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in nonimmune adults: a randomized comparative trial. Am J Trop Med Hyg 2000; 63: 274–9PubMedGoogle Scholar
  256. 256.
    Looareesuwan S, Chulay JD, Canfield CJ, et al. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60: 533–41PubMedGoogle Scholar
  257. 257.
    Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35: 825–33PubMedCrossRefGoogle Scholar
  258. 258.
    Malarone® Prescribing Information [online]. Available from URL: http://www.gsk.com [Accessed 2003 Feb 2]
  259. 259.
    McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003; 59: 545–52PubMedCrossRefGoogle Scholar
  260. 260.
    Boots M, Phillips M, Curtis JR. Megaloblastic anemia and pancytopenia due to Proguanil in patients with chronic renal failure. Clin Nephrol 19820; 18: 106–8PubMedGoogle Scholar
  261. 261.
    Basco LK, LeBras J. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1993; 48: 120–5PubMedGoogle Scholar
  262. 262.
    Long GW, Watt G, Sy N, et al. In vitro drug response of Plasmodium falciparum in the Philippines: increased resistance to amodiaquine. Southeast Asian J Trop Med Public Health 1987; 18: 202–6PubMedGoogle Scholar
  263. 263.
    Brasseur P, Guiguemede R, Diallo S, et al. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg 1999; 93: 645–50PubMedCrossRefGoogle Scholar
  264. 264.
    Basco LK. Inefficacy of amodiaquine against chloroquine-resistant malaria [letter]. Lancet 1991; 338: 1460PubMedCrossRefGoogle Scholar
  265. 265.
    Watt G, Long GW, Padre L, et al. Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines. Am J Trop Med Hyg 1987; 36: 3–8PubMedGoogle Scholar
  266. 266.
    White NJ. Can amodiaquine be resurrected? Lancet 1996; 348: 1184–5PubMedCrossRefGoogle Scholar
  267. 267.
    Adjuik M, Agnamey P, Babiker A, et al. Amodiaquineartesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359: 1365–72PubMedCrossRefGoogle Scholar
  268. 268.
    Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360: 2031–8PubMedCrossRefGoogle Scholar
  269. 269.
    Staedke SG, Kamya MR, Dorsey G, et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001; 358: 368–74PubMedCrossRefGoogle Scholar
  270. 270.
    Orrell C, Taylor WR, Olliaro P. Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 2001; 95: 517–8PubMedCrossRefGoogle Scholar
  271. 271.
    Akindele O, Odejide AO. Amodiaquine-induced involuntary movements. BMJ 1976; 2: 214–5PubMedCrossRefGoogle Scholar
  272. 272.
    Hirst LW, Sanborn G, Green WR, et al. Amodiaquine ocular changes. Arch Opthalmol 1982; 100: 1300–4CrossRefGoogle Scholar
  273. 273.
    Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; I: 411–4CrossRefGoogle Scholar
  274. 274.
    Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. BMJ 1986; 292: 721–3PubMedCrossRefGoogle Scholar
  275. 275.
    Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis: a report of seven cases. Ann Intern Med 1986; 104: 801–3PubMedGoogle Scholar
  276. 276.
    Bepler CR, Baier HN, McCracken S, et al. A 15 month controlled study of the effects of amodiaquine (Camoquin) in rheumatoid arthritis. Arthritis Rheum 1959; 2: 403–13PubMedCrossRefGoogle Scholar
  277. 277.
    Clarke JB, Neftel K, Kitteringham NR, et al. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95: 369–75PubMedCrossRefGoogle Scholar
  278. 278.
    Christie G, Breckenridge AM, Park BK. Drug-protein conjugates: XVIII. detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem Pharmacol 1989; 38: 1451–8PubMedCrossRefGoogle Scholar
  279. 279.
    Luo XD, Shen CC. The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives. Med Res Rev 1987; 7: 29–52PubMedCrossRefGoogle Scholar
  280. 280.
    China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials. Clinical studies on the treatment of malaria with Qinghaosu and its derivatives. J Tradit Chin Med 1982; 2: 45–50Google Scholar
  281. 281.
    White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413–22PubMedGoogle Scholar
  282. 282.
    Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44: 1680–5PubMedCrossRefGoogle Scholar
  283. 283.
    Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives: a review of published and unpublished clinical trials. Med Trop (Mars) 1998; 58(3 Suppl.): 50–3Google Scholar
  284. 284.
    Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60: 547–55PubMedGoogle Scholar
  285. 285.
    Leonardi E, Gilvary G, White NJ, et al. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001; 95: 182–3PubMedCrossRefGoogle Scholar
  286. 286.
    Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251–9PubMedGoogle Scholar
  287. 287.
    Genovese RF, Newman DB, Petras JM, et al. Behavioral and neural toxicity of arteether in rats. Pharmacol Biochem Behav 1998; 60: 449–58PubMedCrossRefGoogle Scholar
  288. 288.
    Petras JM, Young GD, Bauman RA, et al. Arteether-induced brain injury in Macaca mulatta: I. the precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat Embryol (Berl) 2000; 201: 383–97CrossRefGoogle Scholar
  289. 289.
    Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, et al. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am J Trop Med Hyg 1998; 59: 519–22PubMedGoogle Scholar
  290. 290.
    Miller L, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria [letter]. N Engl J Med 1997; 792: 1328CrossRefGoogle Scholar
  291. 291.
    Senanayake N, de Silva HJ. Delayed cerebellar ataxia complicating falciparum malaria: a clinical study of 74 patients. J Neurol 1994; 241: 456–9PubMedCrossRefGoogle Scholar
  292. 292.
    Van Vugt M, Angus BJ, Price RN, et al. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 2000; 62: 65–9PubMedGoogle Scholar
  293. 293.
    Kissinger E, Hien TT, Hung NT, et al. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am J Trop Med Hyg 2000 Jul-Aug; 63(1-2): 48–55PubMedGoogle Scholar
  294. 294.
    Dayan AD. Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? Med Trop (Mars) 1998; 58(3 Suppl.): 32–7Google Scholar
  295. 295.
    WHO. The use of artemisinin and its derivatives as anti-malarial drugs: report of a joint CTD/DMP/TDR informal consultation. Geneva: WHO, 1998 Jun 10–12Google Scholar
  296. 296.
    Wang TY. Therapeutic effectiveness and toxic side effects of artemisinin and artemether for their treatment of malaria patients in pregnancy. J Tradit Chin Med 1989; 9: 28–30PubMedGoogle Scholar
  297. 297.
    Li GQ, Guo XB, Yang F. Clinical trials on qinghasou and its derivatives. Vol 1. China: Guangzhou Medicine Institute, 1990Google Scholar
  298. 298.
    McGready R, Cho T, Cho JJ, et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 1998; 92: 430–3PubMedCrossRefGoogle Scholar
  299. 299.
    Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001; 95: 424–8PubMedCrossRefGoogle Scholar
  300. 300.
    McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000; 94: 689–93PubMedCrossRefGoogle Scholar
  301. 301.
    McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001 Dec 15; 33(12): 2009–16PubMedCrossRefGoogle Scholar
  302. 302.
    World Health Organization. Antimalarial drug combination therapy: report of a WHO technical consultation. WHO/CDS/RBM/2001.35Google Scholar
  303. 303.
    von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 2000; 355: 352–7CrossRefGoogle Scholar
  304. 304.
    Doherty JF, Sadiq AD, Bayo L, et al. A randomized safety and tolerability trial of artesunate plus sulfadoxine: pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 1999; 93: 543–6PubMedCrossRefGoogle Scholar
  305. 305.
    Olliaro P, Taylor WR, Rigal J. Controlling malaria: challenges and solutions. Trop Med Int Health 2001; 6: 22–7CrossRefGoogle Scholar
  306. 306.
    von Seidlein L, Bojang K, Jones P, et al. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am J Trop Med Hyg 1998; 58: 638–44Google Scholar
  307. 307.
    von Seidlein L, Jaffar S, Pinder M, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997; 176: 1113–6CrossRefGoogle Scholar
  308. 308.
    Hatz C, Abdulla S, Mull R, et al. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop Med Int Health 1998; 3: 498–504PubMedCrossRefGoogle Scholar
  309. 309.
    Kshirsagar NA, Gogtay NJ, Moorthy NS, et al. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg 2000; 62: 402–8PubMedGoogle Scholar
  310. 310.
    van Agtmael M, Bouchaud O, Malvy D, et al. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the tropics to The Netherlands and France. Int J Antimicrob Agents 1999; 12: 159–69PubMedCrossRefGoogle Scholar
  311. 311.
    Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60: 936–42PubMedGoogle Scholar
  312. 312.
    Bakshi R, Hermeling-Fritz I, Gathmann I, et al. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 2000; 94: 419–24PubMedCrossRefGoogle Scholar
  313. 313.
    Bindschedler M, Lefevre G, Ezzet F, et al. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 2000; 56: 375–81PubMedCrossRefGoogle Scholar
  314. 314.
    van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999; 61: 964–7PubMedGoogle Scholar
  315. 315.
    Warhurst DC. Why are primaquine and other 8-aminoquinolines particularly effective against the mature gametocytes and the hypnozoites of malaria [short report]. Ann Trop Med Parasitol 1984; 78: 165PubMedGoogle Scholar
  316. 316.
    Pukrittayakamee S, Vanijanonta S, Chantra A, et al. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169: 932–5PubMedCrossRefGoogle Scholar
  317. 317.
    Arnold J, Alving AS, Hockwald RS. The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J Lab Clin Med 1954; 44: 429–38PubMedGoogle Scholar
  318. 318.
    Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55: 243–9PubMedGoogle Scholar
  319. 319.
    Smoak BL, DeFraites RF, Magill AJ, et al. Plasmodium vivax infections in US Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 1997; 56: 231–4PubMedGoogle Scholar
  320. 320.
    Doherty JF, Day JH, Warhurst DC, et al. Treatment of Plasmodium vivax malaria: time for a change [short report]. Trans R Soc Trop Med Hyg 1997; 91: 76PubMedCrossRefGoogle Scholar
  321. 321.
    Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994; 88: 218–9PubMedCrossRefGoogle Scholar
  322. 322.
    Clayman CB, Arnold J, Hockwald RS, et al. Toxicity of primaquine in Caucasians. JAMA 1952; 149: 1563–8CrossRefGoogle Scholar
  323. 323.
    Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull WHO 1981; 59: 391–5PubMedGoogle Scholar
  324. 324.
    Brennecke FE, Alving AS, Arnold J, et al. A preliminary report on the effect of certain 8-aminoquinolines in the treatment of rheumatoid arthritis. Lab Clin Med 1951; 38: 795–6Google Scholar
  325. 325.
    Hansen JE, Cleve EA, Pruitt FW. Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methaemoglobinaemia) due to primaquine. Am J Med Sci 1954; 227: 9–12PubMedCrossRefGoogle Scholar
  326. 326.
    Sietsma Naughton MA, Harley JD. Methaemoglobin levels in soldiers receiving antimalarial drugs. Med J Aust 1971; 27: 473–5Google Scholar
  327. 327.
    Cohen RJ, Sachs JR, Wicker DJ, et al. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med 1968; 279: 1127–31PubMedCrossRefGoogle Scholar
  328. 328.
    Fletcher KA, Evans-Price DA, Gilles HM, et al. Studies on the pharmacokinetics of primaquine. Bull WHO 1981; 149: 1563–8Google Scholar
  329. 329.
    Carson PE, Hohl R, Nora MV, et al. Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. Bull WHO 1981; 59: 427–37PubMedGoogle Scholar
  330. 330.
    Barrett EL. Glucose-6-phosphate dehydrogenase deficiency: a brief review. Trans R Soc Trop Med Hyg 1966; 60: 267–75PubMedCrossRefGoogle Scholar
  331. 331.
    Zalusky R. Drug-associated hemolytic anemia. Bull N Y Acad Med 1970; 46: 427–37PubMedGoogle Scholar
  332. 332.
    Sarkar S, Prakash D, Marwaha RK, et al. Acute intravascular haemolysis in glucose-6-phosphate deficiency. Ann Trop Paediatr 1993; 13: 391–4PubMedGoogle Scholar
  333. 333.
    Hockwald RS, Arnold J, Clayman C, et al. Toxicity of primaquine in Negroes. JAMA 1952; 149: 1568–70CrossRefGoogle Scholar
  334. 334.
    Salvidio E, Pannacciulli I, Tizianello A, et al. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N Engl J Med 1967; 276: 1339–44PubMedCrossRefGoogle Scholar
  335. 335.
    Khoo KK. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol 1981; 75: 591–5PubMedGoogle Scholar
  336. 336.
    Na Bangchang K, Songsaeng W, Thanavibul A, et al. Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. Trans R Soc Trop Med Hyg 1994; 88: 220–2PubMedCrossRefGoogle Scholar
  337. 337.
    Abeyaratne KP, Halpe NL. Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. Ceylon Med J 1968; 27: 134–8Google Scholar
  338. 338.
    Alving AS, Johnson CF, Tarlov AR, et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO 1960; 22: 621–31PubMedGoogle Scholar
  339. 339.
    Vivona S, Brewer GJ, Conrad M, et al. The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria. Bull WHO 1961; 25: 267–9PubMedGoogle Scholar
  340. 340.
    Charoenlarp P, Areekul S, Harinasuta T, et al. The haemolytic effect of a single dose of 45mg of primaquine in G-6PD deficient Thais. J Med Assoc Thailand 1972; 55: 631–8Google Scholar
  341. 341.
    Fryauff DJ, Baird JK, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346: 1190–3PubMedCrossRefGoogle Scholar
  342. 342.
    Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001; 33: 1 90-7Google Scholar
  343. 343.
    Baird JK, Fryauff DJ, Basri H, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52: 479–84PubMedGoogle Scholar
  344. 344.
    Soto J, Toledo J, Rodriquez M, et al. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 241–4PubMedGoogle Scholar
  345. 345.
    Soto J, Toledo J, Rodriquez M, et al. Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin Infect Dis 1999; 29: 199–201PubMedCrossRefGoogle Scholar
  346. 346.
    Weiss WR, Oloo AJ, Johnson A, et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171: 1569–75PubMedCrossRefGoogle Scholar
  347. 347.
    Sin DD, Shafran SD. Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 477–81PubMedCrossRefGoogle Scholar
  348. 348.
    White NJ. The treatment of malaria. N Engl J Med 1996; 335: 802–6CrossRefGoogle Scholar
  349. 349.
    Luzzi GA, Peto TEA. Adverse effects of antimalarials. Drug Saf 1993; 8(4): 295–311PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.WHO/Tropical Disease Research (TDR)Geneva 27Switzerland
  2. 2.Centre for Infectious DiseasesRoyal Free and University College Medical School, Windeyer Institute of Medical SciencesLondonUK
  3. 3.Faculty of Tropical MedicineMahidol UniversityBangkokThailand
  4. 4.Centre for Vaccinology and Tropical MedicineChurchill HospitalOxfordUK

Personalised recommendations